603 related articles for article (PubMed ID: 23046248)
1. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors.
Si D; Luo H; Zhang X; Yang K; Wen H; Li W; Liu J
Bioorg Chem; 2021 Oct; 115():105268. PubMed ID: 34426149
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
[TBL] [Abstract][Full Text] [Related]
4. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
5. Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor.
Miyazaki M; Uoto K; Sugimoto Y; Naito H; Yoshida K; Okayama T; Kawato H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
Bioorg Med Chem; 2015 May; 23(10):2360-7. PubMed ID: 25882531
[TBL] [Abstract][Full Text] [Related]
6. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
7. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
8. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-κB pathway.
Zhuang C; Miao Z; Wu Y; Guo Z; Li J; Yao J; Xing C; Sheng C; Zhang W
J Med Chem; 2014 Feb; 57(3):567-77. PubMed ID: 24428757
[TBL] [Abstract][Full Text] [Related]
9. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.
Miyazaki M; Naito H; Sugimoto Y; Yoshida K; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Shiose Y; Aonuma M; Soga T
Bioorg Med Chem; 2013 Jul; 21(14):4319-31. PubMed ID: 23685175
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC
J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644
[TBL] [Abstract][Full Text] [Related]
13. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
Uesato S; Matsuura Y; Matsue S; Sumiyoshi T; Hirata Y; Takemoto S; Kawaratani Y; Yamai Y; Ishida K; Sasaki T; Enari M
Bioorg Med Chem; 2016 Apr; 24(8):1919-26. PubMed ID: 27010502
[TBL] [Abstract][Full Text] [Related]
15. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
[TBL] [Abstract][Full Text] [Related]
19. Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
Rew Y; Sun D; Yan X; Beck HP; Canon J; Chen A; Duquette J; Eksterowicz J; Fox BM; Fu J; Gonzalez AZ; Houze J; Huang X; Jiang M; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Saiki AY; Shaffer P; Wang YC; Wortman S; Yakowec P; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
J Med Chem; 2014 Dec; 57(24):10499-511. PubMed ID: 25384157
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
